Manap Roslina Abdul, Loh Li Cher, Ismail Tengku Saifudin Tengku, Muttalif Abdul Razak, Simon George Kutty, Toh Rosalind Beng Hong, Norhaya Mohd Razali, Tarekh Noor Aliza Md, Hashim Che Wan Aminuddin, Rani Mohammad Fauzi Abdul, Mahayiddin Aziah Ahmad
Department of Medicine, UniversitiKebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia.
Patient Relat Outcome Meas. 2012;3:71-8. doi: 10.2147/PROM.S19211. Epub 2012 Nov 7.
Budesonide/formoterol used for both maintenance and reliever therapy has been shown to benefit patients with persistent asthma. We evaluated patient satisfaction and asthma control among Malaysian patients prescribed budesonide/formoterol as single maintenance and reliever therapy in a real-life clinical practice.
Adult patients diagnosed with partially controlled or uncontrolled asthma were recruited in a 6-month, prospective, open-label study involving ten hospital-based chest clinics in Malaysia. Patients were prescribed one or two inhalations of budesonide/formoterol Turbuhaler (160/4.5 μg per inhalation) twice daily as maintenance therapy and additional inhalation as reliever therapy. Maintenance doses were decided by physicians based on Global Initiative for Asthma-defined treatment objectives. The primary outcome measure was the change in mean Satisfaction with Asthma Treatment Questionnaire (SATQ) scores from baseline to an average of 3 months and 6 months. Secondary outcome was the change in mean Asthma Control Questionnaire 5-item version (ACQ-5) scores from baseline to an average of 3 months and 6 months and the proportion of patients achieving the minimum clinically important difference.
Of 201 eligible patients recruited, 195 completed the study. Overall, SATQ mean (standard deviation) score was significantly improved from 5.1 (0.76) at baseline to 5.5 (0.58) (P < 0.001). The increase was observed in all domains of SATQ and had occurred at 3 months for most patients. ACQ-5 mean (standard deviation) score was significantly reduced from 2.2 (1.13) at baseline to 1.2 (0.95) (P < 0.001). A total of 132 (67.7.1%) patients had achieved the minimal clinically important difference (≥0.5) of ACQ-5 scores at study end.
In a nationwide study, budesonide/formoterol maintenance and reliever therapy achieved greater patient satisfaction and better asthma control compared with previous conventional asthma regimes among Malaysian patients treated in a real-life practice setting. Such an approach may represent an important treatment alternative for our local patients with persistent asthma.
布地奈德/福莫特罗用于维持治疗和缓解治疗已被证明对持续性哮喘患者有益。我们在现实临床实践中评估了马来西亚接受布地奈德/福莫特罗单一维持和缓解治疗的患者的满意度和哮喘控制情况。
在一项为期6个月的前瞻性开放标签研究中,招募了诊断为部分控制或未控制哮喘的成年患者,该研究涉及马来西亚的十家医院胸科诊所。患者每日两次吸入布地奈德/福莫特罗都保(每次吸入160/4.5μg)作为维持治疗,并按需额外吸入作为缓解治疗。维持剂量由医生根据全球哮喘防治创议确定的治疗目标来决定。主要结局指标是哮喘治疗满意度问卷(SATQ)平均得分从基线到平均3个月和6个月的变化。次要结局是哮喘控制问卷5项版本(ACQ-5)平均得分从基线到平均3个月和6个月的变化以及达到最小临床重要差异的患者比例。
在招募的201名符合条件的患者中,195名完成了研究。总体而言,SATQ平均(标准差)得分从基线时的5.1(0.76)显著提高到5.5(0.58)(P<0.001)。在SATQ的所有领域均观察到得分增加,且大多数患者在3个月时就已出现。ACQ-5平均(标准差)得分从基线时的2.2(1.13)显著降低至1.2(0.95)(P<0.001)。在研究结束时,共有132名(67.7%)患者达到了ACQ-5得分的最小临床重要差异(≥0.5)。
在一项全国性研究中,与以往在现实临床实践环境中治疗马来西亚持续性哮喘患者的传统哮喘治疗方案相比,布地奈德/福莫特罗维持和缓解治疗使患者满意度更高,哮喘控制更好。这种方法可能是我们当地持续性哮喘患者的一种重要治疗选择。